MX2021015528A - Exosomas para el tratamiento de enfermedades. - Google Patents

Exosomas para el tratamiento de enfermedades.

Info

Publication number
MX2021015528A
MX2021015528A MX2021015528A MX2021015528A MX2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A
Authority
MX
Mexico
Prior art keywords
exosomes
disorders
population
conditions
diseases
Prior art date
Application number
MX2021015528A
Other languages
English (en)
Inventor
Qian Ye
Xiaokui Zhang
Bhavani Stout
Shuyang He
Robert J Hariri
Haley M Hariri
Navjot Shah
Srinivas Somanchi
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of MX2021015528A publication Critical patent/MX2021015528A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención proporciona un método para tratar enfermedades, trastornos y afecciones en un sujeto humano que comprende administrar al sujeto una población de exosomas o una composición que comprende una población de exosomas, en donde dicha población de exosomas es positiva para CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4 o sus combinaciones. Tales enfermedades, trastornos y afecciones incluyen enfermedades, trastornos y afecciones de pulmón, hígado, sistema nervioso central, riñón, cardiovasculares, gastrointestinales, del bazo, oculares, sistémicas y asociadas al envejecimiento.
MX2021015528A 2019-06-19 2020-06-19 Exosomas para el tratamiento de enfermedades. MX2021015528A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962863767P 2019-06-19 2019-06-19
US201962891700P 2019-08-26 2019-08-26
US201962905117P 2019-09-24 2019-09-24
US201962924147P 2019-10-21 2019-10-21
PCT/US2020/038828 WO2020257720A1 (en) 2019-06-19 2020-06-19 Exosomes for disease treatment

Publications (1)

Publication Number Publication Date
MX2021015528A true MX2021015528A (es) 2022-02-03

Family

ID=71662298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015528A MX2021015528A (es) 2019-06-19 2020-06-19 Exosomas para el tratamiento de enfermedades.

Country Status (12)

Country Link
US (1) US20230181649A1 (es)
EP (1) EP3986381A1 (es)
JP (1) JP2022538004A (es)
KR (1) KR20220024060A (es)
CN (1) CN114302731A (es)
AU (1) AU2020298316A1 (es)
BR (1) BR112021025512A2 (es)
CA (1) CA3142020A1 (es)
IL (1) IL288958A (es)
MX (1) MX2021015528A (es)
WO (1) WO2020257720A1 (es)
ZA (1) ZA202109828B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
WO2022183047A1 (en) * 2021-02-26 2022-09-01 The Methodist Hospital Regulatory t cell (treg) extracellular vesicle compositions and methods
CN113171379A (zh) * 2021-04-28 2021-07-27 奥启(深圳)创投科技有限公司 一种间充质干细胞外泌体在制备脂肪性肝病药物中的应用
WO2023197011A2 (en) * 2022-04-08 2023-10-12 Jay Rappaport Nampt for wound-healing and stimulating hair growth and/or regrowth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111433352A (zh) * 2017-11-16 2020-07-17 细胞结构公司 用以分离外泌体的胎盘培养

Also Published As

Publication number Publication date
KR20220024060A (ko) 2022-03-03
JP2022538004A (ja) 2022-08-31
BR112021025512A2 (pt) 2022-02-01
WO2020257720A1 (en) 2020-12-24
IL288958A (en) 2022-02-01
CA3142020A1 (en) 2020-12-24
EP3986381A1 (en) 2022-04-27
CN114302731A (zh) 2022-04-08
ZA202109828B (en) 2024-04-24
US20230181649A1 (en) 2023-06-15
AU2020298316A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
ZA202109828B (en) Exosomes for disease treatment
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2022005380A (es) Composiciones que comprenden colina.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
PH12017501420A1 (en) Compositions and methods of tumor treatment utilizing nanoparticles
MY173860A (en) Methods of treating or preventing cholesterol related disorders
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2019011697A (es) Agentes para aumentar la secrecion de lipidos en la glandula de meibomio.
EP4275761A3 (en) Alkaline phosphatase agents for treatment of radiation disorders
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2019000677A (es) Células miméticas de células b.
MX2022003398A (es) Composicion micelar inmunoestimulante.
WO2020041531A3 (en) Oligosaccharide compositions and methods of use thereof for reducing ammonia levels
ZA202103209B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
MX2021013612A (es) Composiciones de oligosacaridos y metodos de uso de las mismas.